SESaba Mohamed El-Gendi

Saba Mohamed El-Gendi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Saba Mohamed El-Gendi has a total of 6 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Ki-67 and Cell Cycle Regulators p53, p63 and cyclinD1 as Prognostic Markers for Recurrence/ Progression of Bladder Urothelial Carcinoma

    by Saba El-Gendi, Ghada Abu-Sheasha

    Deregulation of the cell cycle regulating genes is common in urothelial bladder carcinoma (UBC). We aimed to examine the prognostic significance of ki-67, p53, p63 and cyclinD1expression in UBC and to identify optimal cut-off points to help identifying patients at high risk of tumor recurrence. We evaluated the immunohistochemical expression of ki-67, p53, p63 and cyclinD1 in 100 UBCs. The conventional and the classification and regression trees-guided (CART-guided) methods were utilized to determine the independent predictors of tumor recurrence. The p53 and Ki-67 expression didn’t associate significantly with tumor recurrence.p63 and cyclinD1 exhibited significant hazard ratios. Using CART, no recurrence was observed when p63 was ≥87.5%. The recurrence incidence increased and the disease free survival (DFS) time shortened as the p63 decreased. CyclinD1 associated significantly with tumor recurrence only if p63 was <35%. Using the CART cut-off values¬, cases were categorized into three groups; (groups I: p63 ≥ 35%, II: p63 < 35% and cyclinD1 < 10% and III: p63 < 35% and cyclinD1 ≥ 10%). Group I patients revealed the least incidence of recurrence at the longest DFS. Group III had the worst prognosis followed by Group II. p63 represents a surrogant biomarker to predict UBC recurrence.CyclinD1 can be used only when p63 is <35%. CART proved helpful with data among which the number of cases with positive outcomes is too small relative to the number of studied predictors. Large cohort studies for ki-67 and p53 are recommended to be performed with standardized criteria as regards patients’ characteristics, cut-off values, and follow-up time.


  • Runx2 Expression as a Potential Prognostic Marker in Invasive Ductal Breast Carcinoma

    by Saba Mohamed El-Gendi, Mohamed Farouk Mostafa

    The Runx family of transcription factors has been implicated in cancer progression, both positively and negatively. Recent studies assigned a role for Runx2 in promoting breast cancer metastasis. However, the role of Runx2 during the early stage of breast carcinoma and its association with clinical outcomes remain unknown. Assessing the clinicopathological significance of Runx2 expression in a cohort of breast invasive ductal carcinomas (IDC). The correlation of nuclear Runx2 LI with clinicopathological parameters was assessed in 84 IDCs. To study the association of Runx2 with patient outcomes, in addition to treating it as a continuous variable, Runx2 was categorized by its median value (65) and by an additional two cut-off points determined by ROC curve analyses, at 45 for disease free survival (DFS) and 40 for overall survival (OS). Multivariate Cox regression models were also constructed. We used the best subset regression to identify models that predict DFS and OS with as few predictors as possible, and validation was performed. Based on the “Predicted R2”, the three best models were identified. Using Cox-regression, the interaction between Runx2 and other clinicopathological terms was tested. Runx2 LI was significantly associated only with positive Her-2 status, and did not correlate significantly with other clinicopathological parameters. Although Runx2 LI, in the continuous form and when categorized by the median, did not correlate significantly with DFS and OS; after it was categorized using the optimal cut-off points determined using ROC curve analysis, the patients with Runx2 LI >45 % showed a significantly higher event rate and shorter DFS (P = 0.047), whereas patients with Runx2 LI >40 % showed a significantly shorter OS (P = 0.050). Moreover, Runx2 LI contributed significantly in the models built to predict DFS and OS. For DFS, no interaction terms contributed significantly to the models. However, among stage IV cases, the interaction term between centred Runx2 and ER significantly contributed to the prediction of OS. Runx2 was a significant predictor of OS in this model. Runx2 has a role in biological behaviour and affects the outcome of IDC; therefore, its inhibition may be a new therapeutic strategy. The predictability of Runx2 for OS in stage IV tumours differs with different ER states. The pattern of this difference was not determined because the sample size was not sufficient to allow pattern testing.


  • FGF18 as a potential biomarker in serous and mucinous ovarian tumors

    by Saba El-Gendi, Eman Abdelzaher, Mohamed Farouk Mostafa, Ghada Abu Sheasha

    Fibroblast growth factor 18 (FGF18) has been suggested to play important roles in promoting progression of ovarian high-grade serous carcinoma. Our aim was to investigate FGF18 expression in the whole spectrum of serous and mucinous ovarian tumors, highlighting differences in expression within the adenoma-carcinoma sequence and differences between type I and type II tumors. We also aimed to test the prognostic significance of this expression and its relation to microvessel density (MVD). We evaluated the immunohistochemical expression of FGF18 and CD31 in 103 ovarian tumors and statistically analyzed their association with clinicopathological variables and patients’ outcome. FGF18 score increased significantly within the adenoma-carcinoma sequence for serous and mucinous tumors. MVD increased significantly only among serous tumors. FGF18 and MVD correlated significantly (overall and among serous tumors only) and were significantly higher in type II than type I tumors. Cox regression models were built. Independent predictors could not be determined due to multicollinearity between the predictors. However, the combination of International Federation of Gynecology and Obstetrics (FIGO) stage, ovarian carcinoma type, and/or FGF18 score achieved the highest predictability of poor prognosis. FGF18 could play a role within the adenoma-carcinoma sequence in type I tumors and might modulate angiogenesis among serous tumors. Our findings further augment the differences between type I and type II tumors. The combination of FIGO stage, ovarian carcinoma type, and/or FGF18 score could predict poor prognosis among ovarian carcinoma patients. Our work identifies FGF18 in ovarian neoplasia as a promising field of research, although evaluation of the performance of the developed models is still needed.


  • Open Access

    Immunohistochemical expression of CD44v6 in differentiated thyroid carcinomas

    by Saba Mohamed El-Gendi, Galila Haseeb El Tawil, Samer Saad Bessa, Ali Mohamed Ahmed Kobil

    CD44 is a polymorphic family of cell surface proteoglycans and glycoproteins implicated in cell-to-cell and cell-to-matrix adhesion interactions and tumor metastasis. This study was designed to histopathologically examine and immunohistochemically detect the expression of CD44v6 in differentiated thyroid carcinomas, and its association with clinicopathologic parameters. Forty different thyroid lesions constituted the material of this study. Cases were divided into a malignant (n = 30) and a non-malignant group (n = 10). Immunostaining was manually performed using CD44v6 mouse monoclonal antibody. CD44v6 expression was significantly higher in malignant compared to non-malignant lesions. This significance was not maintained when cases were categorized as neoplastic and non-neoplastic. Female sex and patients age <45 years were significantly associated with higher CD44v6 expression in the malignant group. Papillary thyroid carcinoma (PTC) showed higher CD44v6 expression than follicular thyroid carcinoma (FTC). CD44v6 immunopositivity did not significantly associate with the microscopic variant of PTC and FTC. Also, tumor size failed to relate significantly with CD44v6 expression within the subtypes of PTC and FTC. However, female sex, patient age <45 years, and tumor size between 1-4cms associated with significantly higher CD44v6 expression in the PTCs when compared to non-malignant lesions. In FTCs no significant relationship was observed between CD44v6 immunopositivity and patients’ age, sex, or tumor size. In the non-malignant group no significant relationship was found between CD44v6 immunopositivity and patients’ sex, or age. The background non-neoplastic thyroid tissue was CD44v6 negative in all cases of both groups except for 4 cases of PTCs. Deregulated expression of CD44v6 occurs in differentiated thyroid carcinomas and in benign thyroid nodules. Thus, further studies are warranted to investigate the diagnostic utility of CD44v6 expression in the differentiation of benign from malignant thyroid lesions. Also, the predictive value of CD44v6 deregulated expression in PTC and the occurrence of nodal metastasis needs further verification.